Tang entities report 5,451,800‑share stake in Fulcrum (FULC)
Rhea-AI Filing Summary
Fulcrum Therapeutics, Inc. Schedule 13G: Tang-linked holders report 5,451,800 shares (8.2%). Tang Capital Management, Kevin Tang and affiliated Tang Capital entities report shared voting and dispositive power over 5,451,800 shares of Common Stock. The filing bases the percentage on 66,633,321 shares outstanding as of April 20, 2026 per the company's Form 10-Q.
The statement identifies the filing parties, their addresses, and citizenship; it lists shared voting/dispositive power across Tang Capital Partners entities and confirms signatures by Kevin Tang on June 10, 2026.
Positive
- None.
Negative
- None.
Insights
Concentrated but non‑controlling stake: Tang group holds 8.2% via shared control.
The filing shows a combined position of 5,451,800 shares representing 8.2% of the outstanding common stock using an as‑of anchor of April 20, 2026. Ownership is recorded as shared voting and dispositive power across multiple Tang entities, not sole control.
Future disclosures or transactions by these entities would change the picture; subsequent filings would show any increase or disposition. Cash‑flow treatment is not stated in this excerpt.
Affinity of related entities requires aggregated read for governance impact.
The statement attributes the same 5,451,800 shares to TCM, TCP, TCPI, TCP III, TCP IV and Kevin Tang with shared powers. The filing clarifies entity relationships and shared control language, which is important for voting calculations at shareholder meetings.
Because power is shared, the position is governance‑relevant but not a controlling block per the disclosed 8.2%. Any material changes should appear in subsequent Section 13 filings.
Key Figures
Key Terms
beneficially owned financial
Schedule 13G regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.